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What’s the best treatment setting 
for stable PE patients?
The answer seems to be the outpatient setting.  
Here’s why. 
PRACTICE CHANGER 
Manage patients with acute pulmonary 
embolism (PE) who are hemodynamically 
stable in the outpatient setting to decrease 
adverse events—regardless of their initial risk 
category.1
STRENGTH OF RECOMMENDATION
B: Based upon a good-quality retrospective 
cohort propensity score analysis.
Roy PM, Corsi DJ, Carrier M, et al. Net clinical benefit of hospitaliza-
tion versus outpatient management of patients with acute pulmonary 
embolism. J Thromb Haemost. 2017;15:685-694. 
ILLUSTRATIVE CASE
A 63-year-old woman with a history of hy-
pertension presents to the emergency de-
partment (ED) with acute onset shortness of 
breath and pleuritic chest pain after traveling 
across the country for a work conference. She 
has no history of cancer, liver disease, or renal 
disease. Her blood pressure is 140/80 mm Hg, 
and her heart rate is 90 bpm. You diagnose an 
acute PE in this patient and start anticoagula-
tion. Should you admit her to the hospital to 
decrease morbidity and mortality? 
According to the Centers for Disease Control and Prevention, venous thromboembolism (VTE) affects ap-
proximately 900,000 people each year, and 
approximately 60,000 to 100,000 of these pa-
tients die annually.2 Pulmonary embolism is 
the third leading cause of death from cardio-
vascular disease, following heart attacks and 
strokes.3 Prompt diagnosis and treatment with 
systemic anticoagulation improves patient 
outcomes and decreases the risk of long-term 
complications. 
The 2016 American College of Chest 
Physicians (CHEST) guideline on antithrom-
botic therapy for VTE disease recommends 
home treatment or early discharge over stan-
dard discharge (after the first 5 days of treat-
ment) for patients who meet the following 
clinical criteria: “clinically stable with good 
cardiopulmonary reserve; no contraindica-
tions such as recent bleeding, severe renal 
or liver disease, or severe thrombocytopenia 
(ie,  <70,000/mm3); expected to be compli-
ant with treatment; and the patient feels well 
enough to be treated at home.”3 
The guideline states that various clini-
cal decision tools, such as the Pulmonary 
Embolism Severity Index (PESI), can aid in 
identifying low-risk patients to be consid-
ered for treatment at home. The PESI uses 
age, gender, vital signs, mental status, and a 
history of cancer, lung, and cardiac disease 
to stratify patients by risk.4
A systematic review of 1 randomized con-
trolled trial (RCT) and 7 observational studies 
found that in low-risk patients, outpatient 
treatment was as safe as inpatient treatment.5 
This more recent study determines the net 
clinical benefit of hospitalized vs outpatient 
management in a wider range of patients with 
acute PE, regardless of initial risk.1
STUDY SUMMARY
Hospitalization confers no benefit  
to stable patients with acute PE 
This retrospective, propensity-matched co-
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hort study compared rates of adverse events 
in 1127 patients with acute PE managed in 
the hospital vs outpatient setting.1 Patients 
were classified as outpatients if they were 
discharged from the ED or discharged from 
the hospital within 48 hours of admission. 
Patients were included if a symptomatic 
acute PE was diagnosed via computed to-
mography scan or high-probability ventila-
tion-perfusion scan and excluded if they were 
<19 years of age, diagnosed with a PE dur-
ing hospitalization, had chronic PE, or were 
hemodynamically unstable, among other 
factors. The investigators calculated PESI 
scores for all patients. 
Propensity scores matched patients on 
28 patient characteristics and known risk fac-
tors for adverse events to ensure the groups 
were similar. The primary outcome was rate 
of adverse events, including recurrent VTE, 
major bleeding, or death at 14 days. The sec-
ondary outcome was rates of the above dur-
ing the 3-month follow-up period. 
Of the 1127 eligible patients, 1081 
were included in the matched cohort, with 
576 (53%) treated as hospitalized patients 
and 505 (47%) treated as outpatients. The 
mean age of the matched cohorts was 
63.2 years for the inpatient group and 
63.6 years for the outpatient group. Overall, 
the cohorts were well matched.
The 14-day rate of adverse events was 
higher in hospitalized patients than in out-
patients (13% vs 3.3%; odds ratio [OR] = 5.07; 
95% confidence interval [CI], 1.68-15.28), 
with each of the adverse events that made 
up the primary outcome occurring more 
frequently in the hospitalized group 
(TABLE). The rate of adverse events at 
3 months was also greater for hospitalized 
patients compared with outpatients (21.7% vs 
6.9%; OR = 4.9; 95% CI, 2.62-9.17). The results 
remained similar for high-risk patients (Class 
III-V) based on their PESI score. 
WHAT’S NEW
A higher rate of AEs in those  
treated as inpatients vs outpatients 
This trial supports the CHEST guideline rec-
ommendations3 to manage hemodynamically 
stable patients with acute PE as outpatients. 
It adds to the conversation by demonstrating 
higher rates of adverse events with hospital-
ization, even in high-risk subgroups (PESI 
Class III-V). 
CAVEATS
A good study, but it wasn’t an RCT
While this is a well-designed cohort study, it 
is not a randomized controlled trial (RCT). 
This study defined outpatient management 
as patients discharged from the ED or hos-
pitalized for <48 hours. However, only 59 of 
the 544 patients in the outpatient group were 
early hospital discharges, while the rest were 
never admitted. Finally, a specialized throm-
bosis clinic followed up with the patients 
within 24 hours of discharge, and patients 
had telephone access to specialized health 
care professionals; such organization of care 
contributed to the safe outpatient manage-
ment of these PE patients.
CHALLENGES TO IMPLEMENTATION
Insurance coverage may present an issue
Medication coverage of direct oral antico-
agulants and low molecular weight heparin 
This trial  
supports  
guideline  
recommendations  
to manage  
hemodynamically 
stable patients 
with acute PE as 
outpatients.
TABLE 
Comparison of inpatient vs outpatient treatment of patients with PE 
Hospitalized (%) Outpatient (%) OR
Primary composite outcome 13 3.3 5.07 (95% CI, 1.68-15.28)
Recurrent VTE 1.7 0.6 5.92 (95% CI, 1.25-28.04)
Major bleeding 3.8 0 OR not evaluable
All-cause mortality 8.2 2.8 3.11 (95% CI, 0.88-11.04)
CI, confidence interval; OR, odds ratio; PE, pulmonary embolism; VTE, venous thromboembolism.
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may present a barrier to patients treated in 
the outpatient setting who have no insur-
ance or are insured by certain insurance 
carriers.                   JFP
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